Biotech leaders were supported by newsflow including Creative Medical’s new U.S. patent covering exosome-based immunotherapy for Type 1 diabetes and Iovance’s 66% second-quarter revenue increase. Braveheart also rose after its IPO. Overall, the updates are modestly positive for specific names but unlikely to be broad market-moving.
Biotech leaders were supported by newsflow including Creative Medical’s new U.S. patent covering exosome-based immunotherapy for Type 1 diabetes and Iovance’s 66% second-quarter revenue increase. Braveheart also rose after its IPO. Overall, the updates are modestly positive for specific names but unlikely to be broad market-moving.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
